Pacira Completes Viatris Merger, Revises $287.5 Million Notes and Ends Credit Facility
Pacira amended conversion terms on $287.5 million of outstanding convertible notes, unwound related capped calls for cash payments, and repaid and terminated its credit agreement.
Following completion of its merger with Viatris, Pacira BioSciences amended the conversion terms of its $287.5 million outstanding convertible notes, unwound related capped call transactions for cash payments, and repaid and terminated its credit agreement. The note amendment ties conversion value…